| Lovell, Daniel J |
| Recruiting | N/A | 198 | Canada, US | Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment | Children's Hospital of Philadelphia, Patient-Centered Outcomes Research Institute | Juvenile Spondyloarthritis | 07/26 | 07/27 | | |
NCT02418442: Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry |
|
|
| Recruiting | N/A | 20000 | Europe, Canada, US, RoW | | Duke University, Childhood Arthritis and Rheumatology Research Alliance | Rheumatic Joint Disease | 06/28 | 12/28 | | |
| Chang, Susan M |
NCT00831324: Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma |
|
|
| Recruiting | 2 | 60 | US | everolimus, immunohistochemistry staining method, laboratory biomarker analysis | University of California, San Francisco | Brain Tumor | 01/16 | 01/17 | | |
| Active, not recruiting | 2 | 247 | US | SurVaxM | MimiVax, LLC, Translational Drug Development, Merit | Newly Diagnosed Glioblastoma | 08/24 | 08/24 | | |
NCT03739411: Hyperpolarized Imaging in Diagnosing Participants With Glioma |
|
|
| Recruiting | 1 | 140 | US | Hyperpolarized Carbon C 13 Pyruvate, Hyperpolarized Pyruvate (13C), Magnetic Resonance Imaging, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MRI, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Radiation Therapy, Radiotherapeutics, Radiotherapy, Chemotherapy | Susan Chang, National Cancer Institute (NCI) | Glioma | 06/28 | 06/28 | | |
NCT04540107: Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma |
|
|
| Recruiting | 1 | 300 | US | Hyperpolarized Carbon C 13 Pyruvate, Hyperpolarized 13C-Pyruvate, Hyperpolarized Pyruvate (13C), Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging, 1H- Nuclear Magnetic Resonance Spectroscopic Imaging, 1H-nuclear magnetic resonance spectroscopic imaging, Magnetic Resonance Spectroscopy, MRS, MRS Imaging, MRSI, Proton Magnetic Resonance Spectroscopic Imaging | Susan Chang, GE Healthcare, Sigma-Aldrich, Phillips-Medisize, National Cancer Institute (NCI) | Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma | 01/27 | 01/27 | | |
NCT04019002: Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma |
|
|
| Active, not recruiting | 1 | 17 | US | Hyperpolarized 13C Pyruvate, HP-13C | Susan Chang, National Cancer Institute (NCI) | Glioblastoma Multiforme (GBM) | 09/25 | 09/25 | | |
NCT05851378: Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma |
|
|
| Recruiting | 1 | 40 | US | Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG), Hyperpolarized C13-aKG, HP C13-aKG, Magnetic Resonance Image (MRI), MRI, MRI scan | Robert Bok, MD, PhD, National Cancer Institute (NCI) | Adult Gliomas, Mixed | 04/26 | 04/26 | | |
| Golden, Jeffrey |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
| Completed | 2 | 80 | Europe, US | Orvepitant Maleate, Placebo | Nerre Therapeutics Ltd., Pharm-Olam International | Cough, Idiopathic Pulmonary Fibrosis | 06/24 | 06/24 | | |
NCT05571059: Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | 2 | 128 | US | Ifetroban Sodium, ifetroban, Placebo | Cumberland Pharmaceuticals | Idiopathic Pulmonary Fibrosis | 01/26 | 01/26 | | |
NCT05195918: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients |
|
|
| Recruiting | 1 | 50 | US | EGCG 300 mg + Nintedanib, epigallocatechin-3-gallate + Ofev, EGCG 300 mg + Pirfenidone, epigallocatechin-3-gallate + Esbriet, Placebo 2 capsules + Nintedanib or Pirfenidone, Placebo + Ofev or Esbriet, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone | Hal Chapman, University of Michigan, Cornell University, Massachusetts General Hospital, Temple University, University of Washington, University of Virginia | Idiopathic Pulmonary Fibrosis | 04/26 | 04/26 | | |
| Rosenthal, Philip |
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) |
|
|
| Recruiting | 3 | 50 | Europe, Canada, US | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo | Takeda | Alpha1-Antitrypsin Deficiency | 08/28 | 08/28 | | |
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein |
|
|
| Recruiting | 3 | 160 | Europe, Canada, US, RoW | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride | Takeda, Takeda Development Center Americas, Inc. | Alpha1-Antitrypsin Deficiency | 03/27 | 03/29 | | |
RISE, NCT04729751 / 2020-004628-40: A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). |
|
|
| Completed | 2 | 27 | Europe, US, RoW | Maralixibat, Formerly LUM001 and SHP625 | Mirum Pharmaceuticals, Inc. | Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease | 12/24 | 12/24 | | |
| Recruiting | 2 | 163 | US | High-dose methylprednisolone, Solu-Medrol, Equine anti-thymocyte globulin, ATGAM, Prednisolone, 15 mg/mL oral solution National Drug Code: 62135-250-37, Placebo for prednisolone, Placebo for infusions, 0.9% Sodium chloride, Diphenhydramine, Benadryl, Methylprednisolone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Ann & Robert H Lurie Children's Hospital of Chicago | Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation | 01/26 | 01/27 | | |
DRUMARS, NCT04969185: Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemoprevention |
|
|
| Completed | N/A | 310 | RoW | | University of California, San Francisco, Institut de Recherche en Sciences de la Sante, Burkina Faso | Malaria,Falciparum | 11/21 | 05/23 | | |
| Stock, Peter |
PARADIGM, NCT03977662: Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes |
|
|
| Active, not recruiting | 1/2 | 8 | US | Co-transplantation of PTG with pancreatic islets | Peter Stock, California Institute for Regenerative Medicine (CIRM) | Type 1 Diabetes | 01/26 | 01/26 | | |
| Ko, Andrew |
| Completed | 4 | 9 | US | Perflutren Lipid Microsphere, DEFINITY® | University of Washington | Acute Spinal Cord Injury | 11/23 | 11/23 | | |
| Active, not recruiting | 3 | 243 | US | Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation | SetPoint Medical Corporation | Rheumatoid Arthritis | 05/24 | 10/27 | | |
A021806, NCT04340141: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer |
|
|
| Recruiting | 3 | 352 | Canada, US | Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer | 01/26 | 11/30 | | |
| Active, not recruiting | 3 | 825 | US | Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88 | Pancreatic Cancer Action Network | Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma | 06/27 | 06/27 | | |
PLATINUM, NCT06115499: The Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2/3 | 100 | US | Nab paclitaxel, ABI-007, Abraxane, Albumin-bound Paclitaxel, Protein-bound Paclitaxel, Gemcitabine, Cisplatin, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, CT Scan, Biospecimen Collection | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC V8 | 01/29 | 12/29 | | |
NCT05221320: Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies |
|
|
| Terminated | 2 | 47 | US | Ulixertinib, BVD-523, BVD523, Hydroxychloroquine | BioMed Valley Discoveries, Inc | Tumor, Solid, Gastrointestinal Cancer | 05/24 | 07/24 | | |
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer |
|
|
| Active, not recruiting | 2 | 232 | Europe, US, RoW | DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil | Leap Therapeutics, Inc., BeiGene | Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer | 06/25 | 12/25 | | |
|
|
|
|
|
|
|
NCT05249101: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma |
|
|
| Recruiting | 1/2 | 70 | US | Ivaltinostat, Capecitabine, Xeloda | CG Pharmaceuticals, Inc | Metastatic Pancreatic Adenocarcinoma | 02/26 | 06/26 | | |
RAMP205, NCT05669482: Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 40 | US | avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel, Gemzar, Abraxane | Verastem, Inc. | KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas | 05/25 | 12/25 | | |
| Recruiting | 1 | 39 | US | Hydroxychloroquine, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist | University of Utah, Novartis Pharmaceuticals | Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma | 01/25 | 01/26 | | |
| Recruiting | N/A | 8 | US | Low-level cortical stimulation | University of Washington | Epilepsy, Brain Injury | 08/23 | 08/23 | | |
NCT03289572: Microgrid II - Electrocorticography Signals for Human Hand Prosthetics |
|
|
| Recruiting | N/A | 20 | US | | University of Washington | Epilepsy Intractable | 12/23 | 12/24 | | |
| Sarwal, Minnie |
| Recruiting | N/A | 2000 | US | Urine Collection | University of California, San Francisco, Rush University Medical Center, University of Michigan, University of California | SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury, Kidney Injury | 03/26 | 03/26 | | |
| Khalili, Mandana |
LCN RESCU, NCT05832229: Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States |
|
|
| Recruiting | 2 | 256 | US | Rosuvastatin, Rosuvastatin 20 mg, Rosuvastatin 10 mg | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California | Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C | 11/26 | 11/26 | | |
| Active, not recruiting | N/A | 250 | US | Moderate alcohol cessation, Hepatitis C therapy | University of California, San Francisco | Insulin Resistance | 12/26 | 12/26 | | |
NCT05191446: Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use |
|
|
| Recruiting | N/A | 180 | US | Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use, Usual Care (UC) | University of California, San Francisco, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Liver Diseases, Alcohol Use Disorder | 01/26 | 02/26 | | |
| Recruiting | N/A | 1200 | US | | Northwestern University, The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California, Central Virginia Veterans Healthcare System | Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis | 09/27 | 09/28 | | |
| Young, William B |
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults |
|
|
| Completed | 2 | 797 | NA | ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline | AEON Biopharma, Inc., PPD | Migraine | 06/24 | 08/24 | | |
| Goldsby, Robert |
AOST2031, NCT05235165: Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma |
|
|
| Recruiting | 3 | 250 | Canada, US, RoW | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Questionnaire Administration, Thoracoscopy, Pleuroscopy, Thoracotomy, incision of Chest Wall, Incision of Thorax | Children's Oncology Group, National Cancer Institute (NCI) | Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Osteosarcoma | 03/31 | 03/31 | | |
NCT02617407: Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients |
|
|
| Completed | 1 | 44 | US | Livionex® Dental Gel, Edathamil, PreviDent 5000 plus/Tom's of Maine Children's toothpaste, Over the counter toothpaste, Kolibree Toothbrush | University of California, San Francisco | Dental Plaque | 01/20 | 01/20 | | |
NCT05641961: Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care |
|
|
| Recruiting | N/A | 30 | US | Survivorship mobile application, Survivorship App, Questionnaires | University of California, San Francisco, Swim Across America | Childhood Cancer, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | 04/25 | 04/25 | | |
| Recruiting | N/A | 50000 | Canada, US | | St. Jude Children's Research Hospital, National Cancer Institute (NCI), Fred Hutchinson Cancer Center, Nationwide Children's Hospital, M.D. Anderson Cancer Center, University of Southern California, Children's Hospital Medical Center, Cincinnati, University of California, San Francisco | Cancer | 11/26 | 11/26 | | |
NCT00736749: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies |
|
|
| Recruiting | N/A | 5000 | US | Assessment of Therapy Complications, Questionnaire Administration | Children's Oncology Group, National Cancer Institute (NCI) | Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor | 01/00 | | | |
| Feldman, Harold I |
NCT00304148: SDCC - Prospective Cohort Study of Chronic Renal Insufficiency |
|
|
| Active, not recruiting | N/A | 5499 | US | | University of Pennsylvania, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Johns Hopkins University, Case Western Reserve University, University of Michigan, University of Illinois at Chicago, Tulane University, Kaiser Permanente | Renal Insufficiency, Chronic | 06/28 | 06/28 | | |
| Fong, Lawrence |
| Completed | 2 | 23 | US | Atezolizumab, MPDL3280A | Lawrence Fong, Genentech, Inc., The Bladder Cancer Advocacy Network, Conquer Cancer Foundation, National Cancer Institute (NCI), The V Foundation | Carcinoma, Transitional Cell | 03/23 | 03/23 | | |
NCT03248570: Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects |
|
|
| Completed | 2 | 26 | US | Pembrolizumab, KEYTRUDA, MK-3475, Chemotherapy | University of California, San Francisco, Merck Sharp & Dohme LLC, National Cancer Institute (NCI) | Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer | 09/23 | 09/23 | | |
NCT04064190: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition |
|
|
| Withdrawn | 2 | 48 | US | Vactosertib(TEW-7197)/ Durvalumab | MedPacto, Inc., AstraZeneca | Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma | 12/23 | 12/24 | | |
NCT03007732: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT |
|
|
| Active, not recruiting | 2 | 23 | US | Pembrolizumab, MK-3475, Keytruda, SD-101, Toll-like receptor 9, Leuprolide acetate, Intermittent androgen deprivation therapy, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy, SBRT | David Oh, Prostate Cancer Foundation, Merck Sharp & Dohme LLC, TriSalus Life Sciences, Inc. | Prostatic Neoplasms | 08/25 | 08/25 | | |
NCT03821246: Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 2 | 68 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Tocilizumab, Actemra, Etrumadenant, AB928 | David Oh, Genentech, Inc. | Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer | 02/25 | 02/25 | | |
NCT05018273: Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors |
|
|
| Completed | 1 | 26 | Europe, US | VB10.NEO, Atezolizumab, Tecentriq | Nykode Therapeutics ASA, Genentech, Inc., Vaccibody AS | Solid Tumors, Adult | 10/24 | 10/24 | | |
| Lee, Andrew K |
| Recruiting | 2 | 84 | US | Biological: Solrikitug Low Dose, Biological: Solrikitug Mid Dose, Biological: Solrikitug High Dose, Placebo | Uniquity One (UNI), DevPro Biopharma | Asthma | 04/25 | 08/25 | | |
| Recruiting | 2 | 135 | US | Biological: Solrikitug low dose, Biological: Solrikitug high dose, Placebo | Uniquity One (UNI), DevPro Biopharma | COPD | 04/25 | 08/25 | | |
NCT06598462: A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults with Eosinophilic Esophagitis |
|
|
| Recruiting | 2 | 157 | US, RoW | Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo | Uniquity One (UNI) | Eosinophilic Esophagitis (EoE) | 04/27 | 08/27 | | |
CCTG EN10, NCT05640999: Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER |
|
|
| Recruiting | 2 | 325 | Europe, Canada, US, RoW | Vaginal brachytherapy, Adjuvant radiotherapy (EBRT +/- brachytherapy), Observation | Canadian Cancer Trials Group, Canadian Cancer Clinical Trials Network | Endometrial Cancer | 12/28 | 06/29 | | |
NCT06640920: A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants |
|
|
| Active, not recruiting | 1 | 48 | US | Cohort A, Cohort B, Cohort C, Cohort D | Uniquity One (UNI) | Healthy | 10/24 | 10/24 | | |
NCT06138782: Identifying Networks Underlying Compulsivity in Anorexia Nervosa for Targeting With Neuromodulation |
|
|
| Recruiting | N/A | 20 | US | Repetitive Transcranial Magnetic Stimulation (rTMS) | University of California, San Francisco | Anorexia Nervosa | 09/25 | 09/25 | | |
| Recruiting | N/A | 10 | US | PMT Stereoencephalography (SEEG), Ad-Tech Depth Electrodes, Vercise Genus™ Deep Brain Stimulation (DBS) System | Casey H. Halpern, M.D., Stanford University | Obsessive-Compulsive Disorder | 03/25 | 01/27 | | |
| Recruiting | N/A | 3000 | US | Treatment Recommendation Surveys, 7-gene biosignature | PreludeDx, University of South Florida | DCIS | 12/25 | 12/35 | | |
NCT04958096: Cortical Stimulation to Treat Obsessive Compulsive Disorder |
|
|
| Recruiting | N/A | 15 | US | Standard Therapeutic Deep Brain Stimulation, Cortical Stimulation for PFC, PFC Stimulation, Cortical Stimulation for ACC, OCD Cortical Stimulation | Andrew Moses Lee, MD, PhD | Obsessive-Compulsive Disorder | 08/26 | 08/26 | | |
| Recruiting | N/A | 1400 | US | HeartStart HS1 | Philips Clinical & Medical Affairs Global | Sudden Cardiac Arrest | 12/27 | 12/27 | | |
| Recruiting | N/A | 5000 | US, RoW | Stereotactic radiosurgery, HyperArc SRS | Varian, a Siemens Healthineers Company | Brain Metastases, CNS Neoplasm, CNS Disorder, Intracranial | 12/31 | 12/31 | | |
NCT02070328: Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up |
|
|
| Recruiting | N/A | 300 | US | Registry | Center for Biomedical Research, LLC, Provision Center for Proton Therapy | Cancer | 01/50 | 01/50 | | |
| Wilder-Smith, Petra |
NCT00540774: Optical Sensor for Photodynamic Detection of Oral Pathology |
|
|
| Recruiting | N/A | 2500 | US | detection of oral pathology | University of California, Irvine, National Institute for Biomedical Imaging and Bioengineering (NIBIB), National Institute of Dental and Craniofacial Research (NIDCR), Livionex Inc., Orahealth, National Cancer Institute (NCI) | Mouth Diseases | 12/28 | 12/28 | | |
NCT05470023: Imaging-based Assessment of Oral Biofilm and Gingival Health |
|
|
| Recruiting | N/A | 275 | US | OTC Toothpastes or Mouthrinses | University of California, Irvine | Plaque, Dental, Gingivitis | 12/26 | 12/26 | | |
| Recruiting | N/A | 200 | US | Lumineux Oral Essentials rinse, Listerine rinse | University of California, Irvine | Oral Bacterial Infection, Oral Infection, Microbial Colonization, Viral Infection | 12/27 | 12/27 | | |
| Lu, Ying |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06520176: Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients |
|
|
| Recruiting | 3 | 99 | RoW | Etoposide, VP-16, Cytarabine, Ara-C, Pegfilgrastim, PEG-rhG-CSF, Cyclophosphamide, Cy, G-CSF, Granulocyte Colony Stimulating Factor | The Affiliated People's Hospital of Ningbo University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Jinhua People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital | Multiple Myeloma, Hematopoietic Stem Cell Mobilization | 12/26 | 12/26 | | |
NCT06520163: Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma |
|
|
| Recruiting | 3 | 99 | RoW | Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF, G-CSF, CHOP, Hyper-CVAD, ID-MTX + Ara-C, DA-EPOCH, GDP, GDPE, ICE, DICE | The Affiliated People's Hospital of Ningbo University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Jinhua People's Hospital, The Central Hospital of Lishui City, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital | Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization | 12/26 | 12/26 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 474 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy | Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital | Nasopharyngeal Carcinoma, Radiotherapy; Complications | 05/25 | 05/28 | | |
NCT05084027: Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT |
|
|
| Recruiting | 2 | 50 | RoW | venetoclax combining with fludarabine and melphalan | First Affiliated Hospital of Zhejiang University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial People's Hospital, The affiliated people's hospital of Ningbo University, First Affiliated Hospital of Wenzhou Medical University, Ningbo Hospital of Zhejiang University, The First Affiliated Hospital of Zhejiang Chinese Medical University | Hematologic Malignancy, Older Patients, Allogeneic Hematopoietic Stem Cell Transplantation | 09/22 | 09/24 | | |
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease |
|
|
| Recruiting | 2 | 40 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 10/25 | 04/26 | | |
NCT06455410: GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 216 | RoW | GP, Adebrelimab, concurrent chemoradiotherapy (CCRT) | Sun Yat-sen University | Nasopharyngeal Carcinoma | 06/26 | 06/28 | | |
NCT03118986: RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy |
|
|
| Recruiting | 2 | 200 | Canada, US, RoW | Olanzapine, Placebo Oral Tablet | The Hospital for Sick Children, University of California, San Francisco, Children's Mercy Hospital Kansas City, St. Justine's Hospital, Columbia University, Medical University of South Carolina, CancerCare Manitoba, University of North Carolina, Chapel Hill, Nationwide Children's Hospital | Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology | 03/25 | 04/25 | | |
NCT05422066: Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 2 | 50 | RoW | Selinexor, ATG-010, Xpovio, Rituximab, RiTUXimab Injection, Cyclophosphamide, Cyclophosphamide Injection, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product | Li Zhiming, Antengene Corporation | DLBCL Germinal Center B-Cell Type | 07/25 | 12/25 | | |
|
NCT05842512: Study of ADI-PEG 20 Versus Placebo in Subjects With NASH |
|
|
| Recruiting | 2 | 40 | RoW | ADI-PEG20, Pegargiminase, Placebo | Polaris Group | Nonalcoholic Steatohepatitis (NASH) | 12/27 | 01/28 | | |
NCT02617407: Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients |
|
|
| Completed | 1 | 44 | US | Livionex® Dental Gel, Edathamil, PreviDent 5000 plus/Tom's of Maine Children's toothpaste, Over the counter toothpaste, Kolibree Toothbrush | University of California, San Francisco | Dental Plaque | 01/20 | 01/20 | | |
NCT05528887: Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies |
|
|
| Recruiting | 1 | 10 | RoW | Autologous CAR-T cells, Fludarabine, Fludara, Cyclophosphamide, Cytoxan | The Affiliated People's Hospital of Ningbo University, UTC Therapeutics Inc. | Relapsed/Refractory Hematological Malignancies, Lymphoma, Myeloma, Leukemia | 06/24 | 06/26 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT05510089: Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies |
|
|
| Recruiting | N/A | 62 | RoW | Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF | The Affiliated People's Hospital of Ningbo University | Hematological Malignancy | 05/24 | 12/24 | | |
2022-YAN-030, NCT05536154: Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies |
|
|
| Recruiting | N/A | 68 | RoW | Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF | The Affiliated People's Hospital of Ningbo University | Lymphoma, Multiple Myeloma | 06/24 | 10/24 | | |
NCT05589337: Baduanjin Training for Depression and Anxiety Patients |
|
|
| Recruiting | N/A | 120 | RoW | Baduanjin, Eight-section Brocade, Health education | Shanghai University of Traditional Chinese Medicine, Shanghai Mental Health Center | Depression Symptoms, Anxiety Symptoms | 06/24 | 12/24 | | |
NCT05717790: Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 288 | RoW | Nimotuzumab, h-R3, BIOMAb EGFR, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT | Fourth Affiliated Hospital of Guangxi Medical University, People's Hospital of Baise, Second Affiliated Hospital of Guangzhou Medical University, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin Medical University, China, LiuZhou People's Hospital, The First People's Hospital of Qinzhou, Wuzhou Red Cross Hospital, Affiliated Hospital of Youjiang Medical University for Nationalities | Nasopharyngeal Carcinoma by AJCC V8 Stage | 11/24 | 11/27 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
NCT05355675: The Association of Microbiota Composition With cGVHD After Allo-HSCT |
|
|
| Recruiting | N/A | 300 | RoW | blood sample, stool sample | First Affiliated Hospital of Zhejiang University | Hematopoietic Stem Cell Transplantation, Hematologic Malignancy, Chronic Graft-versus-host-disease, Complication | 05/25 | 05/25 | | |
NCT05940480: TCM Daoyin Therapy in Individuals At-risk for COPD |
|
|
| Recruiting | N/A | 60 | RoW | TCM Daoyin, Qigong, Health education | Shanghai University of Traditional Chinese Medicine, Changzheng Community Health Service Center of Putuo District, Shanghai | Chronic Obstructive Pulmonary Disease, Lung Diseases, Obstructive | 06/27 | 12/27 | | |
| Butowski, Nicholas A |
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo | Chimerix | H3 K27M, Glioma | 08/26 | 08/26 | | |
|
|
| Recruiting | 2/3 | 1030 | Europe, Canada, US, RoW | Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase | Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group | Glioblastoma | 06/26 | 06/28 | | |
|
|
| Active, not recruiting | 2 | 247 | US | SurVaxM | MimiVax, LLC, Translational Drug Development, Merit | Newly Diagnosed Glioblastoma | 08/24 | 08/24 | | |
| Active, not recruiting | 2 | 210 | Europe, US | Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine | CNS Pharmaceuticals, Inc., Worldwide Clinical Trials | Glioblastoma Multiforme, Adult | 12/24 | 03/25 | | |
|
|
| Recruiting | 2 | 250 | Europe, Canada, US, RoW | Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R) | Fore Biotherapeutics, Fore Biotherapeutics | Cancer Harboring BRAF Alterations | 06/25 | 08/26 | | |
NCT05753007: A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients |
|
|
| Recruiting | 2 | 36 | US | Cannabidiol (CBD), Placebo | Mclean Hospital, University of California, San Francisco, Center for Medicinal Cannabis Research | Glioblastoma | 09/25 | 09/25 | | |
DIET2TREAT, NCT05708352: A Phase 2 Study of the Ketogenic Diet Vs Standard Anti-cancer Diet Guidance for Patients with Glioblastoma in Combination with Standard-of-care Treatment |
|
|
| Recruiting | 2 | 170 | US | Keto Diet, Standard Anti-Cancer Diet | Cedars-Sinai Medical Center, National Cancer Institute (NCI) | Glioblastoma Multiforme | 06/28 | 06/29 | | |
| Active, not recruiting | 1/2 | 125 | Europe, US | ST101, Temozolomide, Radiation | Sapience Therapeutics | Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma | 12/24 | 12/25 | | |
NCT06504381: DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma |
|
|
| Not yet recruiting | 1/2 | 70 | US | DB107-RRV, Toca 511, Vocimagene amiretrorepvec, DB107-FC, Toca FC, Extended-release 5-fluorocytosine, 5-fluorocytosine, Radiation Therapy (RT), Radiation Treatment, Temozolomide, Temozolomide (TMZ), Magnetic Resonance Imaging (MRI), MR, MRI, Surgical resection, Surgical tumor resection, Brain surgery | Nicholas Butowski, California Institute for Regenerative Medicine (CIRM) | High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma | 01/40 | 01/40 | | |
| Active, not recruiting | 1/2 | 192 | Europe, US | TNG908 | Tango Therapeutics, Inc., Tango Therapeutics, Inc. | Locally Advanced Solid Tumor | 04/25 | 09/25 | | |
NCT05370508: A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM |
|
|
| Terminated | 1/2 | 8 | US | SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS), Exablate Type 2.0 | SonALAsense, Inc. | Recurrent GBM | 06/24 | 07/24 | | |
NCT02022644: Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma |
|
|
| Completed | 1 | 18 | US | nanoliposomal irinotecan, MM-398, ONIVYDE | University of California, San Francisco, Ipsen, National Cancer Institute (NCI) | High Grade Glioma | 12/20 | 05/23 | | |
NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) |
|
|
| Terminated | 1 | 14 | US | IMA950, IMA950 peptides, poly-ICLC, Hiltonol, Varlilumab, CDX-1127 | Nicholas Butowski, Celldex Therapeutics, National Cancer Institute (NCI) | Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed | 12/22 | 12/22 | | |
FRONTIER, NCT05303467: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM |
|
|
| Active, not recruiting | 1 | 12 | US | TheraSphere GBM, TheraSphere™ GBM Y-90 Glass Microspheres (TheraSphere GBM) | Boston Scientific Corporation | Glioblastoma Multiforme, Recurrent Glioblastoma | 12/24 | 06/25 | | |
NCT04656535: AB154 Combined with AB122 for Recurrent Glioblastoma |
|
|
| Recruiting | 1 | 46 | US | Zimberelimab, Domvanalimab, Placebo | Yale University, National Cancer Institute (NCI), Arcus Biosciences, Inc. | Glioblastoma | 02/25 | 12/25 | | |
NCT05557292: RMC-5552 Monotherapy in Adult Subjects with Recurrent Glioblastoma |
|
|
| Recruiting | 1 | 48 | US | RMC-5552, mTORC1/4EBP1 | Nicholas Butowski, Revolution Medicines, Inc., National Cancer Institute (NCI) | Glioblastoma, Recurrent Glioblastoma | 12/25 | 12/25 | | |
